Design, synthesis and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein

    Authors

    V. M. Shahani; P. B. Yue; S. Fletcher; S. Sharmeen; M. A. Sukhai; D. P. Luu; X. L. Zhang; H. Sun; W. Zhao; A. D. Schimmer; J. Turkson;P. T. Gunning

    Comments

    Authors: contact us about adding a copy of your work at [email protected]

    Abbreviated Journal Title

    Bioorg. Med. Chem.

    Keywords

    STAT3; Peptidomimetics; SH2 domain; Molecular recognition; Anti-cancer; drugs; Protein-protein interactions; EPIDERMAL-GROWTH-FACTOR; BREAST-CARCINOMA CELLS; SIGNAL TRANSDUCER; CONSTITUTIVE ACTIVATION; SMALL-MOLECULE; FLUORESCENCE POLARIZATION; BIOLOGICAL-ACTIVITY; GENE-REGULATION; SH2 DOMAIN; CANCER; Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry, ; Organic

    Abstract

    Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STAT3-mediated molecular events that support the malignant phenotype. To identify novel, STAT3-selective inhibitors suitable for interrogating STAT3 signaling in tumor cells, we explored the design of hybrid molecules by conjugating a known STAT3 inhibitory peptidomimetic, ISS610 to the high-affinity STAT3-binding peptide motif derived from the ILR/gp-130. Several hybrid molecules were examined in in vitro biophysical and biochemical studies for inhibitory potency against STAT3. Lead inhibitor 14aa was shown to strongly bind to STAT3 (K(D) = 900 nM), disrupt STAT3: phosphopeptide complexes (K(i) = 5 mu M) and suppress STAT3 activity in in vitro DNA binding activity/electrophoretic mobility shift assay (EMSA). Moreover, lead STAT3 inhibitor 14aa induced a time-dependent inhibition of constitutive STAT3 activation in v-Src transformed mouse fibroblasts (NIH3T3/v-Src), with 80% suppression of constitutively-active STAT3 at 6 h following treatment of NIH3T3/v-Src. However, STAT3 activity recovered at 24 h after treatment of cells, suggesting potential degradation of the compound. Results further showed a suppression of aberrant STAT3 activity in NIH3T3/v-Src by the treatment with compound 14aa-OH, which is the non-pTyr version of compound 14aa. The effect of compounds 14aa and 14aa-OH are accompanied by a moderate loss of cell viability. (C) 2010 Elsevier Ltd. All rights reserved.

    Journal Title

    Bioorganic & Medicinal Chemistry

    Volume

    19

    Issue/Number

    5

    Publication Date

    1-1-2011

    Document Type

    Article

    Language

    English

    First Page

    1823

    Last Page

    1838

    WOS Identifier

    WOS:000287740200027

    ISSN

    0968-0896

    Share

    COinS
     

    Accessibility Statement

    This item was created or digitized prior to April 24, 2027, or is a reproduction of legacy media created before that date. It is preserved in its original, unmodified state specifically for research, reference, or historical recordkeeping. In accordance with the ADA Title II Final Rule, the University Libraries provides accessible versions of archival materials upon request. To request an accommodation for this item, please submit an accessibility request form.